|
GS170247: MP:0002038 carcinoma
|
|
GS204629: GO:1901564 organonitrogen compound metabolic process
|
|
GS135864: femur length in high growth mice 4 (Feml4, Published QTL Chr 11)
|
|
GS136647: serum IGFBP-5 level QTL 6 (Si5lq6, Published QTL Chr 11)
|
|
GS129172: pregnancy QTL 2 (Pregq2 Published QTL Chr 11)
|
|
GS136853: Theiler's murine encephalomyelitis virus induced demyelinating disease susceptibility 5 (Tmevd5, Published QTL Chr 11)
|
|
GS164506: MP:0001698 decreased embryo size
|
|
GS169830: MP:0005384 cellular phenotype
|
|
GS170328: MP:0003324 increased liver adenoma incidence
|
|
GS165308: MP:0004848 abnormal liver size
|
|
GS135389: body growth early QTL 10 (Bgeq10, Published QTL Chr 11)
|
|
GS191019: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS170021: MP:0011087 complete neonatal lethality
|
|
GS187887: GO:0080090 regulation of primary metabolic process
|
|
GS165992: MP:0008469 abnormal protein level
|
|
GS196735: GO:0006783 heme biosynthetic process
|
|
GS135818: ethanol induced thermoregulation 4 (Ethm4, Published QTL Chr 11)
|
|
GS135496: brain weight QTL 1 (Brwq1, Published QTL Chr 11)
|
|
GS189669: GO:2000112 regulation of cellular macromolecule biosynthetic process
|
|
GS192017: GO:0006139 nucleobase-containing compound metabolic process
|
|
GS166225: MP:0009850 embryonic lethality between implantation and placentation
|
|
GS177404: GO:0005737 cytoplasm
|
|
GS167214: MP:0005319 abnormal enzyme/ coenzyme level
|
|
GS207925: GO:0034645 cellular macromolecule biosynthetic process
|
|
GS201251: GO:0044424 intracellular part
|
|
GS135528: castaneus 10 week body weight 3 (C10bw3, Published QTL Chr 11)
|
|
GS193238: GO:0031323 regulation of cellular metabolic process
|
|
GS203908: GO:0016070 RNA metabolic process
|
|
GS196729: GO:0005789 endoplasmic reticulum membrane
|
|
GS136767: streptozotocin induced diabetes susceptibility (Stzid, Published QTL Chr 11)
|
|
GS162953: MP:0002020 increased tumor incidence
|
|
GS136696: systematic lupus erythematosus susceptibility 13 (Sle13, Published QTL Chr 11)
|
|
GS164258: MP:0002084 abnormal developmental patterning
|
|
GS136481: plasmacytoma susceptibility 3 (Pcyts3, Published QTL Chr 11)
|
|
GS136780: seizure susceptibility 3 (Szs3, Published QTL Chr 11)
|
|
GS193414: GO:0044249 cellular biosynthetic process
|
|
GS164129: MP:0001573 abnormal circulating alanine transaminase level
|
|
GS178922: GO:0003700 sequence-specific DNA binding transcription factor activity
|
|
GS135973: wound healing/regeneration 10 (Heal10, Published QTL Chr 11)
|
|
GS127931: Olfactory bulb - Allen Mouse Brain Atlas
|
|
GS193937: GO:0006366 transcription from RNA polymerase II promoter
|
|
GS168063: MP:0000313 abnormal cell death
|
|
GS164042: MP:0002018 malignant tumors
|
|
GS186744: GO:0043226 organelle
|
|
GS164991: MP:0003674 oxidative stress
|
|
GS182835: GO:0005622 intracellular
|
|
GS166438: MP:0002231 abnormal primitive streak morphology
|
|
GS182703: GO:0051171 regulation of nitrogen compound metabolic process
|
|
GS203406: GO:0009653 anatomical structure morphogenesis
|
|
GS186790: GO:0006725 cellular aromatic compound metabolic process
|
|
GS127934: Retrohippocampal region - Allen Mouse Brain Atlas
|
|
GS199935: GO:0006778 porphyrin-containing compound metabolic process
|
|
GS168683: MP:0000598 abnormal liver morphology
|
|
GS194111: GO:0097159 organic cyclic compound binding
|
|
GS164748: MP:0000603 pale liver
|
|
GS135792: epilepsy 6 (El6, Published QTL Chr 11)
|
|
GS204150: GO:0009611 response to wounding
|
|
GS209323: GO:0042168 heme metabolic process
|
|
GS84255: alcohol preference locus (Published QTL, Chr 11)
|
|
GS87284: Table S8: GENES UPREGULATED AFTER 8 WEEKS DELTAFOSB VS.CONTROLS AND THE EFFECT OF DELTACJUN (Whole Table) [DRG]
provisional
|
|
GS184448: GO:0044425 membrane part
|
|
GS189751: GO:0050794 regulation of cellular process
|
|
GS187343: GO:0006351 transcription, DNA-dependent
|
|
GS127012: Raloxifene interacting genes (MeSH:D020849) in CTD
|
|
GS126584: Tetrachlorodibenzodioxin interacting genes (MeSH:D013749) in CTD
|
|
GS136357: novelty/stress induced locomotor activation 8 (Nsila8, Published QTL Chr 11)
|
|
GS86424: Table S6: GENES UPREGULATED AFTER 8 WEEKS DELTAFOSB VS.CONTROLS AND THE EFFECT AT 1, 2 AND 4 WEEKS [DRG]
provisional
|
|
GS181473: GO:0005488 binding
|
|
GS87150: Table S6: GENES UPREGULATED AFTER 8 WEEKS DELTAFOSB VS.CONTROLS AND THE EFFECT AT 1, 2 AND 4 WEEKS [DRG]
provisional
|
|
GS166294: MP:0011109 partial lethality throughout fetal growth and development
|
|
GS207616: GO:0016020 membrane
|
|
GS168685: MP:0009395 increased nucleated erythrocyte cell number
|
|
GS169389: MP:0002060 abnormal skin morphology
|
|
GS167542: MP:0001790 abnormal immune system physiology
|
|
GS129115: collagen induced arthritis 40 (Cia40 Published QTL Chr 11)
|
|
GS166640: MP:0000609 abnormal liver physiology
|
|
GS197244: GO:0044237 cellular metabolic process
|
|
GS198456: GO:0019438 aromatic compound biosynthetic process
|
|
GS136831: TNF-induced lethal shock susceptibility 2 (Tilss2, Published QTL Chr 11)
|
|
GS125639: Acrolein interacting genes (MeSH:D000171) in CTD
|
|
GS194088: GO:0003676 nucleic acid binding
|
|
GS165527: MP:0005378 growth/size phenotype
|
|
GS127938: Striatum - Allen Mouse Brain Atlas
|
|
GS136477: periosteal circumference 2 (Pcir2, Published QTL Chr 11)
|
|
GS135274: "alcohol preference locus 18, male specific" (Alcp18, Published QTL Chr 11)
|
|
GS186740: GO:0043229 intracellular organelle
|
|
GS196540: GO:0043565 sequence-specific DNA binding
|
|
GS135823: ethanol conditioned taste aversion 9 (Etohcta9, Published QTL Chr 11)
|
|
GS188506: GO:0010467 gene expression
|
|
GS208012: GO:0044464 cell part
|
|
GS201252: GO:0044425 membrane part
|
|
GS135766: experimental allergic encephalomyelitis susceptibility 7 (Eae7, Published QTL Chr 11)
|
|
GS201239: GO:0046483 heterocycle metabolic process
|
|
GS192073: GO:1901576 organic substance biosynthetic process
|
|
GS188399: GO:0044238 primary metabolic process
|
|
GS865: Sey_Pax6_Age_Reduced_Linear_Incr
|
|
GS184435: GO:0046483 heterocycle metabolic process
|
|
GS166194: MP:0009931 abnormal skin appearance
|
|
GS123718: Ethinyl Estradiol interacting genes (MeSH:D004997) in CTD
|
|
GS164515: MP:0001693 failure of primitive streak formation
|
|
GS177310: GO:1901360 organic cyclic compound metabolic process
|
|
GS136543: periosteal circumference 2 (Pstc2, Published QTL Chr 11)
|
|
GS169535: MP:0005397 hematopoietic system phenotype
|
|
GS169833: MP:0005380 embryogenesis phenotype
|
|
GS191151: GO:0010556 regulation of macromolecule biosynthetic process
|
|
GS127928: Lateral septal complex - Allen Mouse Brain Atlas
|
|
GS178448: GO:0005634 nucleus
|
|
GS199635: GO:0005622 intracellular
|
|
GS127935: Striatum dorsal region - Allen Mouse Brain Atlas
|
|
GS125187: Sulindac interacting genes (MeSH:D013467) in CTD
|
|
GS163077: MP:0010274 increased organ/body region tumor incidence
|
|
GS136328: non-insulin-dependent diabetes mellitus 4 (Nidd4, Published QTL Chr 11)
|
|
GS165244: MP:0010771 integument phenotype
|
|
GS196941: GO:0008150 biological_process
|
|
GS199634: GO:0005623 cell
|
|
GS164136: MP:0000001 mammalian phenotype
|
|
GS124695: arsenic trioxide interacting genes (MeSH:C006632) in CTD
|
|
GS126287: Estrogens interacting genes (MeSH:D004967) in CTD
|
|
GS166150: MP:0001577 anemia
|
|
GS163946: MP:0011106 partial embryonic lethality between implantation and somite formation
|
|
GS187045: GO:0016070 RNA metabolic process
|
|
GS201256: GO:0044422 organelle part
|
|
GS136337: nicotine induced locomotor activity 2 (Nilac2, Published QTL Chr 11)
|
|
GS162897: MP:0003984 embryonic growth retardation
|
|
GS166794: MP:0002941 increased circulating alanine transaminase level
|
|
GS201431: GO:0005515 protein binding
|
|
GS136708: semilethal sex-restricted (Slthsr, Published QTL Chr 11)
|
|
GS165615: MP:0002123 abnormal hematopoiesis
|
|
GS136514: protein kinase C content in lungs (Pkccl, Published QTL Chr 11)
|
|
GS126276: pirinixic acid interacting genes (MeSH:C006253) in CTD
|
|
GS136560: QTL for body weight independent of sex 3 (Qbis3, Published QTL Chr 11)
|
|
GS166947: MP:0001683 absent mesoderm
|
|
GS169170: MP:0001860 liver inflammation
|
|
GS136086: kidney weight QTL 15 (Kwq15, Published QTL Chr 11)
|
|
GS163575: MP:0000203 abnormal circulating aspartate transaminase level
|
|
GS177761: GO:0044271 cellular nitrogen compound biosynthetic process
|
|
GS165868: MP:0002139 abnormal hepatobiliary system physiology
|
|
GS86584: Table S8: GENES UPREGULATED AFTER 8 WEEKS DELTAFOSB VS.CONTROLS AND THE EFFECT OF DELTACJUN [DRG]
provisional
|
|
GS208406: GO:0042440 pigment metabolic process
|
|
GS168551: MP:0002429 abnormal blood cell morphology/development
|
|
GS209564: GO:0043231 intracellular membrane-bounded organelle
|
|
GS136048: insulin dependent diabetes susceptibility 4 (Idd4, Published QTL Chr 11)
|
|
GS169827: MP:0005387 immune system phenotype
|
|
GS165160: MP:0006207 embryonic lethality during organogenesis
|
|
GS163523: MP:0003333 liver fibrosis
|
|
GS135507: body weight QTL 4 (Bw4, Published QTL Chr 11)
|
|
GS205047: GO:0006807 nitrogen compound metabolic process
|
|
GS184629: GO:0005515 protein binding
|
|
GS169603: MP:0001672 abnormal embryogenesis/ development
|
|
GS136566: retinoic acid induced forelimb autopod reduction (Rafar, Published QTL Chr 11)
|
|
GS167108: MP:0008942 abnormal induced cell death
|
|
GS135386: berghei resistance locus 2 (Berr2, Published QTL Chr 11)
|
|
GS169421: MP:0002447 abnormal erythrocyte morphology
|
|
GS180152: GO:0065007 biological regulation
|
|
GS170601: MP:0005621 abnormal cell physiology
|
|
GS135366: B.burgdorferi-associated arthritis 4 (Bbaa4, Published QTL Chr 11)
|
|
GS135353: Alzheimer's disease modifier 5 (Azdm5, Published QTL Chr 11)
|
|
GS196806: GO:0032502 developmental process
|
|
GS129196: Tmc1 modifier 2 (Tmc1m2 Published QTL Chr 11)
|
|
GS84253: alcohol preference locus (Published QTL, Chr 11)
|
|
GS164108: MP:0008019 increased liver tumor incidence
|
|
GS127927: Hypothalamus - Allen Mouse Brain Atlas
|
|
GS203594: GO:0043226 organelle
|
|
GS135276: "alcohol preference locus 20, female specific" (Alcp20, Published QTL Chr 11)
|
|
GS205364: GO:0010467 gene expression
|
|
GS163760: MP:0003331 hepatocellular carcinoma
|
|
GS210002: GO:0044444 cytoplasmic part
|
|
GS209009: GO:1901576 organic substance biosynthetic process
|
|
GS166502: MP:0003186 abnormal redox activity
|
|
GS190949: GO:0009058 biosynthetic process
|
|
GS165537: MP:0005376 homeostasis/metabolism phenotype
|
|
GS197644: GO:0006954 inflammatory response
|
|
GS164746: MP:0000601 small liver
|
|
GS203593: GO:0043227 membrane-bounded organelle
|
|
GS136632: small effect CIA locus 6 (Secia6, Published QTL Chr 11)
|
|
GS177308: GO:1901362 organic cyclic compound biosynthetic process
|
|
GS135555: CD8 memory T cell subset 4 (Cd8mts4, Published QTL Chr 11)
|
|
GS124744: icariin interacting genes (MeSH:C056599) in CTD
|
|
GS136439: peak bone density 1 (Pbd1, Published QTL Chr 11)
|
|
GS182404: GO:0031224 intrinsic to membrane
|
|
GS197319: GO:0003712 transcription cofactor activity
|
|
GS136220: mandible length 12 (Manln12, Published QTL Chr 11)
|
|
GS210000: GO:0044446 intracellular organelle part
|
|
GS127924: Cerebral cortex - Allen Mouse Brain Atlas
|
|
GS127925: Hippocampal formation - Allen Mouse Brain Atlas
|
|
GS167588: MP:0008412 increased cellular sensitivity to oxidative stress
|
|
GS194087: GO:0003674 molecular_function
|
|
GS170351: MP:0006208 lethality throughout fetal growth and development
|
|
GS177356: GO:0003674 molecular_function
|
|
GS178885: GO:0003677 DNA binding
|
|
GS207615: GO:0016021 integral to membrane
|
|
GS203590: GO:0043229 intracellular organelle
|
|
GS135295: acute lung injury QTL 1 (Aliq1, Published QTL Chr 11)
|
|
GS177309: GO:1901363 heterocyclic compound binding
|
|
GS87088: Table S8: GENES UPREGULATED AFTER 8 WEEKS DELTAFOSB VS.CONTROLS AND THE EFFECT OF DELTACJUN [DRG]
provisional
|
|
GS135678: compensatory renal hypertrophy QTL 1 (Crhq1, Published QTL Chr 11)
|
|
GS188410: GO:0032774 RNA biosynthetic process
|
|
GS164672: MP:0010297 increased hepatobiliary system tumor incidence
|
|
GS180166: GO:0008152 metabolic process
|
|
GS1256: Gene Expression in Human Hippocampus from Cocaine Addicts
|
|
GS203072: GO:0090304 nucleic acid metabolic process
|
|
GS204631: GO:1901566 organonitrogen compound biosynthetic process
|
|
GS83981: cocaine related behavior 12 (Cocrb12, Published QTL, Chr 11)
|
|
GS179957: GO:0005783 endoplasmic reticulum
|
|
GS209024: GO:0000988 protein binding transcription factor activity
|
|
GS84254: nicotine sensitivity (Published QTL,Chr 11)
|
|
GS136517: platelet count 2 (Pltct2, Published QTL Chr 11)
|
|
GS177382: GO:0097159 organic cyclic compound binding
|
|
GS195678: GO:0003700 sequence-specific DNA binding transcription factor activity
|
|
GS127937: Striatum-like amygdalar nuclei - Allen Mouse Brain Atlas
|
|
GS86636: Table S6: GENES UPREGULATED AFTER 8 WEEKS DELTAFOSB VS.CONTROLS AND THE EFFECT AT 1, 2 AND 4 WEEKS [DRG]
provisional
|
|
GS136896: visual placing (Vispl, Published QTL Chr 11)
|
|
GS206909: GO:0006952 defense response
|
|
GS127936: Striatum ventral region - Allen Mouse Brain Atlas
|
|
GS166295: MP:0005343 increased circulating aspartate transaminase level
|
|
GS190714: GO:0016020 membrane
|
|
GS187751: GO:0019222 regulation of metabolic process
|
|
GS195214: GO:0009987 cellular process
|
|
GS163934: MP:0001764 abnormal homeostasis
|
|
GS204204: GO:0006351 transcription, DNA-dependent
|
|
GS200648: GO:0044260 cellular macromolecule metabolic process
|
|
GS165525: MP:0010768 mortality/aging
|
|
GS170442: MP:0010866 abnormal prenatal body size
|
|
GS185259: GO:0051252 regulation of RNA metabolic process
|
|
GS203642: GO:0006725 cellular aromatic compound metabolic process
|
|
GS210114: GO:0033013 tetrapyrrole metabolic process
|
|
GS135461: bone mineral density 7 (Bomd7, Published QTL Chr 11)
|
|
GS207923: GO:0034641 cellular nitrogen compound metabolic process
|
|
GS136244: methamphetamine response QTL 3 (Marq3, Published QTL Chr 11)
|
|
GS198263: GO:0005488 binding
|
|
GS194040: GO:1901360 organic cyclic compound metabolic process
|
|
GS86932: Table S3: CORTEX 17K MICROARRAY [DRG]
|
|
GS135755: experimental allergic encephalomyelitis susceptibility 22 (Eae22, Published QTL Chr 11)
|
|
GS190067: GO:0018130 heterocycle biosynthetic process
|
|
GS197025: GO:0044432 endoplasmic reticulum part
|
|
GS165524: MP:0010769 abnormal survival
|
|
GS169609: MP:0001674 abnormal triploblastic development
|
|
GS135341: atherosclerosis 19 (Ath19, Published QTL Chr 11)
|
|
GS204928: GO:0042175 nuclear outer membrane-endoplasmic reticulum membrane network
|
|
GS205266: GO:0032774 RNA biosynthetic process
|
|
GS165243: MP:0010770 preweaning lethality
|
|
GS166535: MP:0010865 prenatal growth retardation
|
|
GS179777: GO:0043565 sequence-specific DNA binding
|
|
GS194267: GO:0043170 macromolecule metabolic process
|
|
GS210357: GO:0044249 cellular biosynthetic process
|
|
GS180452: GO:0044237 cellular metabolic process
|
|
GS127939: Thalamus - Allen Mouse Brain Atlas
|
|
GS164247: MP:0001680 abnormal mesoderm development
|
|
GS195570: GO:0046983 protein dimerization activity
|
|
GS206953: GO:0018130 heterocycle biosynthetic process
|
|
GS194499: GO:0044271 cellular nitrogen compound biosynthetic process
|
|
GS123768: Cyclosporine interacting genes (MeSH:D016572) in CTD
|
|
GS180164: GO:0008150 biological_process
|
|
GS177357: GO:0003676 nucleic acid binding
|
|
GS168995: MP:0009642 abnormal blood homeostasis
|
|
GS177531: GO:0043170 macromolecule metabolic process
|
|
GS199936: GO:0006779 porphyrin-containing compound biosynthetic process
|
|
GS167505: MP:0008762 embryonic lethality
|
|
GS209023: GO:0000989 transcription factor binding transcription factor activity
|
|
GS205255: GO:0044238 primary metabolic process
|
|
GS207858: GO:0009059 macromolecule biosynthetic process
|
|
GS194434: GO:0051186 cofactor metabolic process
|
|
GS127930: Midbrain - Allen Mouse Brain Atlas
|
|
GS127933: Pons - Allen Mouse Brain Atlas
|
|
GS164262: MP:0002080 prenatal lethality
|
|
GS164511: MP:0001697 abnormal embryo size
|
|
GS184218: GO:0071704 organic substance metabolic process
|
|
GS183514: GO:0019219 regulation of nucleobase-containing compound metabolic process
|
|
GS183848: GO:0044260 cellular macromolecule metabolic process
|
|
GS186757: GO:0034654 nucleobase-containing compound biosynthetic process
|
|
GS164257: MP:0002085 abnormal embryonic tissue morphology
|
|
GS136433: pulmonary adenoma susceptibility 5a (Pas5a, Published QTL Chr 11)
|
|
GS208954: GO:0006139 nucleobase-containing compound metabolic process
|
|
GS167109: MP:0008943 increased sensitivity to induced cell death
|
|
GS190950: GO:0009059 macromolecule biosynthetic process
|
|
GS166154: MP:0011098 complete embryonic lethality during organogenesis
|
|
GS178461: GO:0009987 cellular process
|
|
GS193061: GO:0044444 cytoplasmic part
|
|
GS192624: GO:0043231 intracellular membrane-bounded organelle
|
|
GS186743: GO:0043227 membrane-bounded organelle
|
|
GS210507: GO:0006950 response to stress
|
|
GS136605: spinal bone mineral density 4 (Sbmd4, Published QTL Chr 11)
|
|
GS169973: MP:0002006 tumorigenesis
|
|
GS193268: GO:0005575 cellular_component
|
|
GS194039: GO:1901363 heterocyclic compound binding
|
|
GS188190: GO:0006807 nitrogen compound metabolic process
|
|
GS127923: Cerebellum - Allen Mouse Brain Atlas
|
|
GS163271: MP:0006042 increased apoptosis
|
|
GS136798: total body bone mineral density 5 (Tbbmd5, Published QTL Chr 11)
|
|
GS205002: GO:0048856 anatomical structure development
|
|
GS136208: liver weight QTL 9 (Lwq9, Published QTL Chr 11)
|
|
GS190713: GO:0016021 integral to membrane
|
|
GS86494: Table S1: Hippocampus 17 K microarray data. [DRG]
|
|
GS207857: GO:0009058 biosynthetic process
|
|
GS126685: Methotrexate interacting genes (MeSH:D008727) in CTD
|
|
GS201023: GO:0071704 organic substance metabolic process
|
|
GS166706: MP:0002166 altered tumor susceptibility
|
|
GS124165: Hydrogen Peroxide interacting genes (MeSH:D006861) in CTD
|
|
GS191106: GO:0044464 cell part
|
|
GS186227: GO:0090304 nucleic acid metabolic process
|
|
GS168593: MP:0002088 abnormal embryonic growth/weight/body size
|
|
GS121893: Vitamin E interacting genes (MeSH:D014810) in CTD
|
|
GS203607: GO:0034654 nucleobase-containing compound biosynthetic process
|
|
GS169114: MP:0004196 abnormal prenatal growth/weight/body size
|
|
GS168710: MP:0001648 abnormal apoptosis
|
|
GS136901: ventral midbrain iron content 6 (Vmbic6, Published QTL Chr 11)
|
|
GS185585: GO:0044710 single-organism metabolic process
|
|
GS168056: MP:0002628 hepatic steatosis
|
|
GS196726: GO:0005783 endoplasmic reticulum
|
|
GS204232: GO:0001071 nucleic acid binding transcription factor activity
|
|
GS168502: MP:0002058 neonatal lethality
|
|
GS135815: ethanol induced ataxia 10 (Etax10, Published QTL Chr 11)
|
|
GS196284: GO:0012505 endomembrane system
|
|
GS195643: GO:0003677 DNA binding
|
|
GS210113: GO:0033014 tetrapyrrole biosynthetic process
|
|
GS127926: Hippocampal region - Allen Mouse Brain Atlas
|
|
GS136952: weight gain in high growth mice 7 (Wg7, Published QTL Chr 11)
|
|
GS202415: GO:0044710 single-organism metabolic process
|
|
GS135812: estradiol regulated response QTL 3 (Estq3, Published QTL Chr 11)
|
|
GS127932: Pallidum - Allen Mouse Brain Atlas
|
|
GS194133: GO:0005737 cytoplasm
|
|
GS166437: MP:0002230 abnormal primitive streak formation
|
|
GS169024: MP:0001654 hepatic necrosis
|
|
GS195199: GO:0005634 nucleus
|
|
GS167500: MP:0000208 decreased hematocrit
|
|
GS189240: GO:2001141 regulation of RNA biosynthetic process
|
|
GS205628: GO:0046148 pigment biosynthetic process
|
|
GS135906: gonadal fat pad weight QTL 1 (Gfpq1, Published QTL Chr 11)
|
|
GS165535: MP:0005370 liver/biliary system phenotype
|
|
GS169774: MP:0001846 increased inflammatory response
|
|
GS136119: body length 6 (Lgth6, Published QTL Chr 11)
|
|
GS185492: GO:0050789 regulation of biological process
|
|
GS136528: prion disease incubation time 3 (Prdt3, Published QTL Chr 11)
|
|
GS136388: autoimmune orchitis resistance 3 (Orch3, Published QTL Chr 11)
|
|
GS136957: weight 5 (Wght5, Published QTL Chr 11)
|
|
GS125090: monomethylarsonous acid interacting genes (MeSH:C406082) in CTD
|
|
GS166772: MP:0002596 abnormal hematocrit
|
|
GS194442: GO:0051188 cofactor biosynthetic process
|
|
GS164127: MP:0001570 abnormal circulating enzyme level
|
|
GS169205: MP:0003717 pallor
|
|
GS165869: MP:0002138 abnormal hepatobiliary system morphology
|
|
GS136789: tail length QTL 8 (Tailq8, Published QTL Chr 11)
|
|
GS127929: Medulla - Allen Mouse Brain Atlas
|
|
GS181667: GO:0019438 aromatic compound biosynthetic process
|
|
GS165163: MP:0006205 embryonic lethality between implantation and somite formation
|
|
GS188511: GO:0010468 regulation of gene expression
|
|
GS169767: MP:0002396 abnormal hematopoietic system morphology/development
|
|
GS184447: GO:0044424 intracellular part
|
|
GS193236: GO:0031326 regulation of cellular biosynthetic process
|
|
GS209863: GO:0050896 response to stimulus
|
|
GS163080: MP:0010273 increased classified tumor incidence
|
|
GS191021: GO:0034645 cellular macromolecule biosynthetic process
|
|
GS195036: GO:0031090 organelle membrane
|
|
GS164534: MP:0002019 abnormal tumor incidence
|
|
GS210212: GO:0005575 cellular_component
|
|
GS188762: GO:0009889 regulation of biosynthetic process
|
|
GS124805: decitabine interacting genes (MeSH:C014347) in CTD
|
|
GS125820: 4-hydroxy-2-nonenal interacting genes (MeSH:C027576) in CTD
|
|
GS187370: GO:0001071 nucleic acid binding transcription factor activity
|
|
GS162925: MP:0010383 increased adenoma incidence
|
|
GS164261: MP:0002081 perinatal lethality
|
|
GS169708: MP:0005416 abnormal circulating protein level
|
|
GS194038: GO:1901362 organic cyclic compound biosynthetic process
|
|
GS170366: MP:0000245 abnormal erythropoiesis
|
|
GS136677: skull morphology 16 (Skull16, Published QTL Chr 11)
|
|
GS182834: GO:0005623 cell
|
|
GS136434: pulmonary adenoma susceptibility 5b (Pas5b, Published QTL Chr 11)
|
|
GS199201: GO:0031224 intrinsic to membrane
|
|
GS135702: dopamine uptake transporter binding 4 (Dautb4, Published QTL Chr 11)
|
|
GS169773: MP:0001845 abnormal inflammatory response
|
|
GS189460: GO:0060255 regulation of macromolecule metabolic process
|
|
GS168012: MP:0010832 lethality during fetal growth through weaning
|
|
GS26324: Differential expression of genes in hippocampus of human cocaine abusers
|
|
GS178537: GO:0006355 regulation of transcription, DNA-dependent
|
|
GS125280: 3,4-dihydroxyphenylethanol interacting genes (MeSH:C005975) in CTD
|
|
GS196943: GO:0008152 metabolic process
|